Moderate-quality evidence from 1 study that detected fractures radiographically showed that zoledronic acid reduced vertebral fractures in osteoporotic men In women, some bisphosphonates alendronate, risedronate, and zoledronic acid reduce vertebral, nonvertebral, and hip fractures. The overall quality of evidence was downgraded to low owing to indirectness. Bisphosphonates are associated with adverse effects, including mild gastrointestinal symptoms, atypical subtrochanteric fractures, and osteonecrosis of the jaw.

Current evidence does not show any benefit for bone density monitoring during treatment. Moderate-quality evidence showed that women treated with antiresorptive treatment including bisphosphonates, raloxifene, and teriparatide benefited from reduced fractures with treatment, even if there was no increase in BMD or if BMD decreased.

There was no evidence for BMD monitoring for men. Moderate-quality evidence showed that menopausal estrogen treatment did not reduce fracture risk in postmenopausal women with established osteoporosis. Evidence from a previous systematic review showed that estrogen decreased fracture risk; however, many of these studies focused on postmenopausal women with low bone density, or on postmenopausal women in general rather than those with established osteoporosis. Estrogen treatment is associated with serious harms, such as increased risk for cerebrovascular accidents and venous thromboembolism, and these harms significantly outweigh the potential benefits.

Although raloxifene has some benefit in reducing vertebral fractures, it does not reduce hip fracture or nonvertebral fractures and is associated with serious harms, including thromboembolism. Low-quality evidence showed that treatment with risedronate in women with osteopenia defined as a T score of —1. This effect is similar to fracture reductions seen in women with osteoporosis undergoing the similar treatment. Duration of treatment in these studies was 1. Although the current evidence is limited to a post hoc evaluation of risedronate in women with advanced osteopenia, the CGC believes that the benefit of fracture reduction is likely to be similar across all bisphosphonates, on the basis of data in osteoporotic women.

However, the efficacy of other bisphosphonates has not been directly evaluated in osteopenic women, and no study has been conducted to primarily assess the effects of fracture prevention in women with osteopenia. The rate of progressive bone loss and the risk for fracture range widely across the osteopenic spectrum and according to additional factors, such as age. The risk for severe adverse effects increases with prolonged use of bisphosphonates. Given the limited evidence supporting benefit, the balance of benefits and harms of treating osteopenic women is most favorable when the risk for fracture is high.

Women younger than 65 years with osteopenia and women older than 65 years with mild osteopenia T score between —1. Clinicians can use their own judgment based on risk factors for fracture, or they can use a risk assessment tool. Factors that increase the risk for fracture in women include lower body weight, smoking, weight loss, family history of fractures, decreased physical activity, alcohol or caffeine use, low calcium and vitamin D intake, and corticosteroid use 7 , , Comparative effectiveness trials evaluating pharmacologic treatments for low bone density or osteoporosis are lacking.

One post hoc analysis of a trial with raloxifene showed that treatment efficacy did not vary according to FRAX score , and at age 75 years, the risk reduction for vertebral fracture was similar across FRAX scores. The current evidence does not support frequent monitoring of women with normal bone density for osteoporosis, because data showed that most women with normal DXA scores did not progress to osteoporosis within 15 years. The data also do not support monitoring BMD during the initial 5 years of treatment in patients receiving pharmacologic agents to treat osteoporosis.

Clinicians should select generic drugs to treat osteoporotic patients when possible Table 2. This guideline update is based on an AHRQ evidence report and an update of the systematic review , The key questions addressed are:. What are the comparative benefits in fracture reduction among various pharmacologic treatments for low bone density? How does fracture risk reduction resulting from treatments vary between individuals with different risks for fracture, as determined by the following factors:. What are the short- and long-term harms of the various treatments when used specifically to treat or prevent low bone density or osteoporotic fracture?

Do these vary by any specific subpopulations? How often should patients be monitored via measurement of BMD during therapy, and how does the antifracture benefit vary with long term continued use of pharmacotherapy? Evidence was further updated specifically for bisphosphonates, calcium, vitamin D, and estrogen through 12 July Only RCTs and published systematic reviews of RCTs that met inclusion criteria were included in the assessment of effectiveness. Where no RCTs were available, large observational studies with more than participants , systematic reviews, and case reports for rare events were included for example, assessment of effects in subgroups or assessment of particular serious adverse events.

The overall quality of evidence and strength of recommendations was graded according to ACPs' clinical practice guidelines grading system Studies were limited to those conducted in adults older than 18 years, healthy adults, those with low bone density, or those with osteoporosis. Pharmacologic agents approved for use in the United States including bisphosphonates alendronate, risedronate, ibandronate, and zoledronic acid , teri-paratide, raloxifene, and menopausal estrogen therapy; the biologic agent denosumab; dietary and supplemental calcium and vitamin D; and physical activity.

The efficacy or effectiveness of the intervention in question were compared with that of placebo or another potency or dosing schedule for the same agent or another agent in the same or another class. Outcomes evaluated include reduction in fracture total, vertebral, nonvertebral, spine, hip, wrist, other and adverse events.

The target audience for this guideline is all clinicians. The target patient population is all adult men and women with low bone density or osteoporosis. The evidence reviews also underwent a peer review process through the journal. The guideline underwent a peer review process through the journal and was posted online for comments from ACP Regents and ACP Governors, who represent physician members at the national and international level.

Search Strategy 1 Bisphosphonates. Search Strategy 3 Monitoring. Search Strategy 5 Other Treatments. Database Searched and Period Covered. Search Strategy 6 Adverse Events. Osteoporosis Prevention, Diagnosis, and Therapy. Assessment of osteoporosis at the primary health-care level. What is osteoporosis and what causes it? Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General.

Update of a Report. Comparative Effectiveness Review no. Agency for Healthcare Research and Quality; March Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: Comparative effectiveness of pharmacologic treatments to prevent fractures: A pilot study using machine learning and domain knowledge to facilitate comparative effectiveness review updating. Agency for Healthcare Research and Quality; September The development of clinical practice guidelines and guidance statements of the American College of Physicians: Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Dose-response relationships for alendronate treatment in osteoporotic elderly women.

Alendronate Elderly Osteoporosis Study Centers. Alendronate vs calcium for treatment of osteoporosis in postmenopausal women [abstract]. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities.

A randomized, double-blind, placebo-controlled trial. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial.

Alendronate Osteoporosis Prevention Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Fosamax International Trial Study Group. Alendronate treatment of established primary osteoporosis in men: Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients CFOS trial. Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis AAC-Trial.

Meta-analyses of therapies for postmenopausal osteoporosis. Meta-analysis of alendronate for the treatment of postmenopausal women. Prevention of nonvertebral fractures by alendronate. Alendronate Osteoporosis Treatment Study Groups. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

Effect of osteoporosis treatments on risk of non-vertebral fractures: Anti-hip fracture efficacy of biophosphonates: Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. Prevention of vertebral fractures in osteoporosis: Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Alendronate and estrogen effects in postmenopausal women with low bone mineral density.

There was a problem providing the content you requested

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of Alendronate improves bone mineral density in primary biliary cirrhosis: Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.

Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: Once-weekly risedronate in men with osteoporosis: Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: Efficacy of risedronate in men with primary and secondary osteoporosis: A 2-year phase II study with 1-year of follow-up of risedronate NE in postmenopausal osteoporosis.

Risedronate therapy prevents corticosteroid-induced bone loss: Risedronate reverses bone loss in postmenopausal women with low bone mass: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: Risedronate prevents bone loss in early postmenopausal women: Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass [abstract].

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. Risedronate increases bone mass in an early postmenopausal population: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.

Risedronate prevents new vertebral fractures in postmenopausal women at high risk. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.

Long-term efficacy of risedronate: Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.

Dried Plums, Prunes and Bone Health: A Comprehensive Review

Efficacy and tolerability of once-weekly administration of The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. Intravenous zoledronate improves bone density in adults with cystic fibrosis CF.

Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.

Osteoporosis Treatment, Symptoms, Pathophysiology Nursing Care NCLEX Lecture

Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: Ibandronate for the prevention of nonvertebral fractures: Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: The effect on bone mass and bone markers of different doses of ibandronate: Effect of ibandronate on bone loss and renal function after kidney transplantation. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Monthly oral ibandronate therapy in postmenopausal osteoporosis: Intravenous ibandronate injections in postmenopausal women with osteoporosis: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.

Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: Sustainability of anti-fracture efficacy and safety of denosumab in postmenopausal osteoporosis [abstract]. Denosumab treatment of postmenopausal women with osteoporosis for 7 years: Denosumab reduced osteoporotic fractures in postmenopausal women with osteoporosis with prior fracture: Denosumab DMab treatment for 6 years maintains low fracture incidence in women greater-than or equal to 75 years with postmenopausal osteoporosis PMO [abstract].

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Discontinuation of denosumab and associated fracture incidence: Discontinuing denosumab treatment does not increase fracture risk. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk—a meta-analysis.

Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: The effect of teriparatide [human parathyroid hormone ] therapy on bone density in men with osteoporosis. Preventing the first vertebral fracture in postmenopausal women with low bone mass usting PTH Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis.

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Parathyroid hormone added to established hormone therapy: Effects of raloxifene on fracture risk in postmenopausal women: Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Raloxifene for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Alendronate and atrial fibrillation: Effect of calcium supplementation on fracture risk: Osteoporosis in primary biliary cirrhosis: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.

Calcium intake and hip fracture risk in men and women: Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: Randomised controlled trial of calcium and supplementation with cholecalciferol vitamin D 3 for prevention of fractures in primary care.

Effects of calcium supplementation on clinical fracture and bone structure: Reappraisal of Katsuragi calcium study, a prospective, double-blind, placebo-controlled study of the effect of active absorbable algal calcium AAACa on vertebral deformity and fracture. Vitamin D 3 and calcium to prevent hip fractures in elderly women.

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Combined calcium and vitamin D 3 supplementation in elderly women: Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. The effect of fluoride and calcium on spinal bone mineral content: A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: Effect of calcium or 25OH vitamin D 3 dietary supplementation on bone loss at the hip in men and women over the age of The effects of calcium supplementation milk powder or tablets and exercise on bone density in postmenopausal women.

Correcting calcium nutritional deficiency prevents spine fractures in elderly women. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis.

Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. Patient level pooled analysis of 68 patients from seven major vitamin D fracture trials in US and Europe. Efficacy of vitamin D 3 supplementation in preventing fractures in elderly women: Fracture prevention with vitamin D supplementation: Hip fracture risk in relation to vitamin D supplementation and serum hydroxyvitamin D levels: Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based, randomized, double-blind, placebo-controlled trial.

Vitamin D supplementation and the prevention of fractures and falls: Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: Prevention of nonvertebral fractures with oral vitamin D and dose dependency: The effect of cholecalciferol vitamin D 3 on the risk of fall and fracture: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: The effects of an open design on trial participant recruitment, compliance and retention—a randomized controlled trial comparison with a blinded, placebo-controlled design.

Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. Two-year randomized controlled trial of vitamin K 1 phylloquinone and vitamin D 3 plus calcium on the bone health of older women. Clinical, biochemical and histological results of a double-blind trial with 1,dihydroxyvitamin D 3 , estradiol and placebo in post-menopausal osteoporosis. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than mg daily. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial.

The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D 3: Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D 3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: Does 1,25 OH 2 D 3 accelerate spinal bone loss?

A controlled therapeutic trial in year-old women. HRT and vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Preventing fractures among older people living in institutional care: Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha OH -vitamin D 3.

Effects of 1 alpha-hydroxyvitamin D 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D 3 in elderly patients with Parkinson's disease.

Effect of four monthly oral vitamin D 3 cholecalciferol supplementation on fractures and mortality in men and women living in the community: Effects of the combined use of calcitonin and 1 alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: A case study of discordant overlapping meta-analyses: A meta-analysis of high dose, intermittent vitamin D supplementation among older adults.

Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. It has been shown that latitude affects risk of osteoporotic fracture. About 22 million women and 5. The EU spends 37 billion euros per year in healthcare costs related to osteoporosis, and the US spends an estimated 19 billion USD annually for related healthcare costs. The link between age-related reductions in bone density and fracture risk goes back at least to Astley Cooper , and the term "osteoporosis" and recognition of its pathological appearance is generally attributed to the French pathologist Jean Lobstein.

Anthropologists have studied skeletal remains that showed loss of bone density and associated structural changes that were linked to a chronic malnutrition in the agricultural area in which these individuals lived. Osteoporosis means "porous bones", from Greek: From Wikipedia, the free encyclopedia. Osteoporosis Elderly woman with osteoporosis showing a curved back from compression fractures of her back bones.

Archived from the original on 18 May Retrieved 16 May Prevention and management of osteoporosis: Archived PDF from the original on 16 July The Cochrane Database of Systematic Reviews 1: Archived from the original on 27 April Retrieved 18 May The Medical Clinics of North America. Systematic Review to Update the U. Agency for Healthcare Research and Quality.

Pharmacology for women's health. Jones and Bartlett Publishers. Archived from the original on 8 September Harrison's principles of internal medicine.


  • Osteoporosis - Wikipedia?
  • Creative Confidence: Unleashing the Creative Potential Within Us All.
  • .

Larry,, Kasper, Dennis L. Dan Louis , , Loscalzo, Joseph Twentieth ed. Archived from the original on 5 August Retrieved 31 March Archived from the original on 14 October Archived from the original on 10 January Current Opinion in Endocrinology, Diabetes and Obesity. Archived from the original on 24 August Journal of the National Medical Association.

Am J Clin Nutr. Archived from the original on 24 April A Story Beyond Calcium". Journal of the American College of Nutrition. Archived from the original on 7 August Retrieved 6 October Archived from the original on 24 October The Journal of Nutrition. A review of recent human research". Current Opinion in Lipidology. An essential nutrient for bone health".

Archived from the original on 10 March A longitudinal and cross-sectional observational study". The Journal of Clinical Endocrinology and Metabolism. British Journal of Sports Medicine. The Framingham Osteoporosis Study". Diagnosis and Treatment of Osteoporosis, 5th edition". Institute for Clinical Systems Improvement.

Archived from the original PDF on 18 July Archived from the original on 19 December N Engl J Med. Eur J Endocrinol Review. Archived from the original on 16 February The Journal of the American Osteopathic Association. Archived from the original on 4 March Retrieved 23 April Clin Nutr Res Review. Archived from the original on 18 January Archived from the original on 8 August Retrieved 5 August A deadly triad in neurodegeneration".

Royal College of Physicians of London. Archived from the original PDF on 14 January Retrieved 3 October Archived from the original on 23 March Usefulness and Perspectives for Clinicians". Archived from the original on 2 June May Archived 15 June at the Wayback Machine. Preventive Services Task Force March Annals of Internal Medicine. Archived from the original on 5 May Consumption of prunes as a source of dietary fiber in men with milk hypercholesterolemia.

Comparative effects of dried plum and dried apple on bone in postmenopausal women. The effect of two doses of dried plum on bone density and bone biomarkers in osteopenic postmenopausal women: A randomized, controlled trial. Dried plums improve indices of bone formation in postmenopausal women. Womens Health Gend Based Med. The effect of dried plum on serum levels of receptor activator of NF-kappaB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: A randomised controlled trial. The effects of a 6-month resistance training and dried plum consumption intervention on strength, body composition, blood markers of bone turnover, and inflammation in breast cancer survivors.

Combining fructooligosaccharide and dried plum has the greatest effect on restoring bone mineral density among select functional foods and bioactive compounds. Comparison of dried plum supplementation and intermittent PTH in restoring bone in osteopenic orchidectomized rats. Dried plum reverses bone loss in an osteopenic rat model of osteoporosis. Dietary dried plum increases bone mass in adult and aged male mice. Addition of fructooligosaccharides and dried plum to soy-based diets reverses bone loss in the ovariectomized rat.

The phenolic acids of Agen prunes dried plums or Agen prune juice concentrates do not account for the protective action on bone in a rat model of postmenopausal osteoporosis. Effects of plum extract on skeletal system of fetal and newborn mice. Plum and soy aglycon extracts superior at increasing bone calcium retention in ovariectomized Sprague Dawley rats. Dried plum diet protects from bone loss caused by ionizing radiation. Dietary dried plum increases bone mass, suppresses proinflammatory cytokines and promotes attainment of peak bone mass in male mice. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.

Dried plums prevent ovariectomy-induced bone loss in rats. Dried plum polyphenols inhibit osteoclastogenesis by downregulating NFATc1 and inflammatory mediators. Evidence for anti-inflammatory and antioxidative properties of dried plum polyphenols in macrophage RAW Craniofacial, limb, and abdominal anomalies in a distinct syndrome: Relation to the spectrum of Pfeiffer syndrome type 3.

Navigation menu

Sonographic findings in a case of cloverleaf skull deformity and prune belly. Familial segregation of cervical ribs, Sprengel anomaly, preaxial polydactyly, anal atresia, and urethral obstruction: Clinical aspects of the prognosis of skull and brain injuries. A study of cases. Pediatric applications of augmentation cystoplasty: The Johns Hopkins experience. Functional outcome of AO type C distal humeral fractures. Dried plum, an emerging functional food that may effectively improve bone health.

Homo erectus and the limits of a paleontological species. Polyostotic hyperostosis in a plum-headed parakeet Psittacula cyanocephala L. Central precocious puberty and chronic renal failure: A reversible condition post renal transplantation. Lower limb deformity due to failed trauma treatment corrected with the Ilizarov technique: Factors affecting the complication rate in 52 patients. Urethral obstruction malformation complex: Phytonutrients for bone health during ageing. Surgical repair of pectus excavatum. Fruits and dietary phytochemicals in bone protection.

Osteoporosis

Skull plasty to correct congenital craniosynostosis. Cranial vault reconstruction of plagiocephaly. Total calvarial reconstruction for sagittal synostosis. Dried plums and their products: Composition and health effects—An updated review.

Electro-acupuncture combined with plum-blossom needle tapping for treatment of supraorbital neuritis-a clinical observation of 59 cases. Combination of acupuncture with cupping increases life quality of patients of osteoporosis. Flavonoid intake and bone health. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: Support Center Support Center. Please review our privacy policy. Significant increase in BMD at the spine and ulna in both groups, however increases were significantly greater in the DP group compared to dried apple control.

No significant differences between groups or any group-by-time interaction. After surgery to establish bone loss, rats placed on various diets supplemented with 13 different combinations of fructooligosaccharides and DP vs.


  • Dried Plums, Prunes and Bone Health: A Comprehensive Review.
  • Guideline Focus and Target Population.
  • Who Wants To Live Forever?.
  • The Scandalous Life of a True Lady.
  • Tudor Costume and Fashion (Dover Fashion and Costumes)?

DPs induced a significant increase in vertebra and femoral BMD compared to controls. Higher femur connectivity density, femur and vertebral linear attenuation. Higher cortical thickness and cortical area. Lower average von Mises stresses. Compared to OVX controls: Harlan Sprague Dawley mice. Within both adult and old mice, increasing DP supplementation was associated with greater BV.

1. Introduction

High and low chlorogenic acid dried plum P. Female rats High and low chlorogenic acid dried plum P. High chlorogenic acid DP juice group had significantly higher trabecular distal BMD compared to controls. Both high and low chlorogenic acid DP juice and DP juice concentrate lead to higher urinary calcium excretion compared to controls. Pregnant mice were fed DP extracts vs.